{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T12:25:52Z","timestamp":1793795152702,"version":"4.6.1"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Many patients with advanced solid tumors ultimately develop resistance to conventional therapies, with especially limited options for those experiencing rapid progression or poor performance status, highlighting the need for personalized immunotherapies capable of inducing durable responses. In this retrospective case series, we describe the clinical course and outcomes of five adults (4 male, 1 female; median age 58 years [range, 39 -62]) with metastatic solid tumors who achieved complete and durable remission following doubly loaded autologous dendritic cell therapy after failure of standard treatments, such as immune checkpoint inhibition, radiation, surgery, or endocrine therapy. Five patients, including prostate adenocarcinoma (n=1), malignant melanoma (n=2), triple-negative breast cancer (n=1), and urothelial carcinoma (n=1), were treated between July 2022 and March 2025 at a single-site referral-based immunotherapy center (Immunocine Cancer Center). Over the course of six weeks, patients received three vaccines of approximately 5\u20137 million modified dendritic cells injected adjacent to the lymph node draining to the tumor site. Follow-up ranged from 6 to 28 months, where radiographic response, clinical performance status, and tumor and available clinical and biological biomarkers were assessed. All five patients achieved complete or near complete radiographic remission confirmed by PET\/CT or histology, with sustained responses ranging from 6 to 28 months and ongoing in all cases, and no grade 3 or higher adverse events observed. These observations support further evaluation of doubly-loaded autologous dendritic cell therapy in larger, controlled studies.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1886898","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T05:35:03Z","timestamp":1786426503000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Primed dendritic cell immunotherapy for multiple solid tumors"],"prefix":"10.3389","volume":"17","author":[{"given":"Jeffrey","family":"Jones","sequence":"first","affiliation":[{"name":"Department of Urology or Immunology, Baylor College of Medicine","place":["Houston, TX, United States"]},{"name":"Urology Section, Michael E DeBakey Veterans Affairs Medical Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aly","family":"Alrabaa","sequence":"additional","affiliation":[{"name":"Long School of Medicine, University of Texas Health Science Center San Antonio","place":["San Antonio, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Decker","sequence":"additional","affiliation":[{"name":"Department of Urology or Immunology, Baylor College of Medicine","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Ferbeyre","sequence":"additional","affiliation":[{"name":"Immunocine Cancer Center","place":["Canc\u00fan, Q.R., Mexico"]},{"name":"Onco Center Cancun","place":["Canc\u00fan, Q.R., Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregorio","family":"Viramontes","sequence":"additional","affiliation":[{"name":"Immunocine Cancer Center","place":["Canc\u00fan, Q.R., Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Immunocine Cancer Center","place":["Canc\u00fan, Q.R., Mexico"]},{"name":"ReHealth","place":["Canc\u00fan, Q.R., Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elideth","family":"Angulo","sequence":"additional","affiliation":[{"name":"Immunocine Cancer Center","place":["Canc\u00fan, Q.R., Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Zamudio","sequence":"additional","affiliation":[{"name":"Immunocine Cancer Center","place":["Canc\u00fan, Q.R., Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Amerimed Hospital","place":["Canc\u00fan, Q.R., Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Noga","sequence":"additional","affiliation":[{"name":"Immunocine Cancer Center","place":["Canc\u00fan, Q.R., Mexico"]},{"name":"Oncology Department, University of Maryland Medical Center","place":["Cantonsville, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Hernandez-Reyes","sequence":"additional","affiliation":[{"name":"Immunocine Cancer Center","place":["Canc\u00fan, Q.R., Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Zhang","sequence":"additional","affiliation":[{"name":"Omega Precision Oncology","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darryl","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Urology or Immunology, Baylor College of Medicine","place":["Houston, TX, United States"]},{"name":"Urology Section, Michael E DeBakey Veterans Affairs Medical Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ara","family":"Karamanian","sequence":"additional","affiliation":[{"name":"HALO Precision Diagnostics (Prostate Laser Center)","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Tamara","sequence":"additional","affiliation":[{"name":"Urology Section, Michael E DeBakey Veterans Affairs Medical Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalton","family":"Greenwood","sequence":"additional","affiliation":[{"name":"Immunocine Cancer Center","place":["Canc\u00fan, Q.R., Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanaja","family":"Konduri","sequence":"additional","affiliation":[{"name":"Department of Urology or Immunology, Baylor College of Medicine","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Halpert","sequence":"additional","affiliation":[{"name":"Immunocine Cancer Center","place":["Canc\u00fan, Q.R., Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0002","article-title":"Measures of outcome in metastatic breast cancer: insights from a real-world scenario","volume":"19","author":"Bonotto","year":"2014","journal-title":"Oncologist"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21409","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-15-1399","article-title":"Dendritic cell-based immunotherapy: state of the art and beyond","volume":"22","author":"Bol","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/ph14080713","article-title":"68Ga]Ga-PSMA-11: The first FDA-approved 68Ga-radiopharmaceutical for PET imaging of prostate cancer","volume":"14","author":"Hennrich","year":"2021","journal-title":"Pharm (Basel)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.21.27323","article-title":"Head-to-head comparison of 68Ga-PSMA-11 PET\/CT and 99mTc-MDP bone scintigraphy for the detection of bone metastases in patients with prostate cancer: a meta-analysis [published correction appears in AJR Am J Roentgenol. 2022 Sep;219(3):529. doi: 10.2214\/AJR.22.28240","volume":"219","author":"Zhao","year":"2022","journal-title":"AJR Am J Roentgenol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2013.00293","article-title":"Rationale for stereotactic body radiation therapy in treating patients with oligometastatic hormone-na\u00efve prostate cancer","volume":"3","author":"Bhattasali","year":"2013","journal-title":"Front Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-025-00947-y","article-title":"Stereotactic body radiotherapy: a second chance for radio-recurrent prostate cancer","volume":"28","author":"Vial","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3001","article-title":"Breast cancer immunotherapy: facts and hopes","volume":"24","author":"Emens","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz127","article-title":"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up","volume":"30","author":"Fradet","year":"2019","journal-title":"Ann Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.7147","article-title":"Current landscape of immunotherapy in breast cancer: a review","volume":"5","author":"Adams","year":"2019","journal-title":"JAMA Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00860-8","article-title":"Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial","volume":"405","author":"Qi","year":"2025","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2007.07.014","article-title":"Phase I\/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma","volume":"125","author":"Kim","year":"2007","journal-title":"Clin Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2013.11.013","article-title":"Open-label, multi-center, non-randomized, single-arm study to evaluate the safety and efficacy of dendritic cell immunotherapy in patients with refractory solid Malignancies, on supportive care","volume":"16","author":"Bapsy","year":"2014","journal-title":"Cytotherapy"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10588","article-title":"Cancer vaccines in the clinic","volume":"9","author":"Janes","year":"2023","journal-title":"Bioeng Transl Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02265","article-title":"Dendritic cell cancer therapy: vaccinating the right patient at the right time","volume":"9","author":"van Willigen","year":"2018","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1423510","article-title":"The mARS complex: a critical mediator of immune regulation and homeostasis","volume":"15","author":"Amanya","year":"2024","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201903002R","article-title":"MHC class I and II peptide homology regulates the cellular immune response","volume":"34","author":"Halpert","year":"2020","journal-title":"FASEB J"},{"key":"B26","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/s41419-020-02794-2","article-title":"Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer","volume":"11","author":"Zhou","year":"2020","journal-title":"Cell Death Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.489922","article-title":"Small-angle X-ray solution scattering study of the multi-aminoacyl-tRNA synthetase complex reveals an elongated and multi-armed particle","volume":"288","author":"Dias","year":"2013","journal-title":"J Biol Chem"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-185470","article-title":"Th-1 polarization is regulated by dendritic-cell comparison of MHC class I and class II antigens","volume":"113","author":"Decker","year":"2009","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01801","article-title":"AIMp1 potentiates TH1 polarization and is critical for effective antitumor and antiviral immunity","volume":"8","author":"Liang","year":"2018","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abc3196","article-title":"A subset of cytotoxic effector memory T cells enhances CAR T cell efficacy in a model of pancreatic ductal adenocarcinoma","volume":"13","author":"Konduri","year":"2021","journal-title":"Sci Transl Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.613204","article-title":"CD8+CD161+ T-cells: cytotoxic memory cells with high therapeutic potential","volume":"11","author":"Konduri","year":"2021","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.2014","article-title":"Vaccination by homologous antigenic loading with DOC1021 as adjuvant therapy for glioblastoma: phase I clinical trial results","volume":"43","author":"Georges","year":"2025","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2013.18","article-title":"Evaluation of RNA amplification methods to improve DC immunotherapy antigen presentation and immune response","volume":"2","author":"Slagter-J\u00e4ger","year":"2013","journal-title":"Mol Ther Nucleic Acids"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.01.029","article-title":"Double loading of dendritic cell MHC class I and MHC class II with an AML antigen repertoire enhances correlates of T-cell immunity in vitro via amplification of T-cell help","volume":"24","author":"Decker","year":"2006","journal-title":"Vaccine"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1089\/scd.2016.0009","article-title":"Dendritic cell-secreted cytotoxic T-lymphocyte-associated protein-4 regulates the T-cell response by downmodulating bystander surface B7","volume":"25","author":"Halpert","year":"2016","journal-title":"Stem Cells Dev"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-019-0080-3","article-title":"Dendritic cell vaccination plus low-dose doxorubicin for the treatment of spontaneous canine hemangiosarcoma","volume":"26","author":"Konduri","year":"2019","journal-title":"Cancer Gene Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2024.102642","article-title":"Evaluation of a multigenomic liquid biopsy (PROSTest) for prostate cancer detection and follow-up in a Caribbean population","volume":"92","author":"Rosin","year":"2024","journal-title":"Cancer Epidemiol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24858","article-title":"Clinical sensitivity and specificity of the PROSTest in an American cohort","volume":"85","author":"Rahbar","year":"2025","journal-title":"Prostate"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.649863","article-title":"Immune checkpoint inhibitors-related thyroid dysfunction: epidemiology, clinical presentation, possible pathogenesis, and management","volume":"12","author":"Zhan","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study","volume":"36","author":"Anichini","year":"2018","journal-title":"J Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"B42","doi-asserted-by":"publisher","first-page":"104604","DOI":"10.1016\/j.critrevonc.2024.104604","article-title":"Synergistic effects of immunotherapy and adjunctive therapies in prostate cancer management","volume":"207","author":"Chen","year":"2024","journal-title":"Crit Rev Oncology\/Hematology"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061353","article-title":"Immune system alterations in multiple myeloma: molecular mechanisms and therapeutic strategies to reverse immunosuppression","volume":"13","author":"D\u00edaz-Tejedor","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.627379","article-title":"Metastatic spread in prostate cancer patients influencing radiotherapy response","volume":"10","author":"Klusa","year":"2021","journal-title":"Front Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2017.12.007","article-title":"Re-emergence of dendritic cell vaccines for cancer treatment","volume":"4","author":"Saxena","year":"2018","journal-title":"Trends Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2018.03.007","article-title":"Dendritic cell-based immunotherapy for solid tumors","volume":"11","author":"Jung","year":"2018","journal-title":"Transl Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1522755","article-title":"High tumor CD161 expression predicts a survival advantage and marks a Th1-skewed microenvironment","volume":"16","author":"Burns","year":"2025","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1084\/jem.191.10.1777","article-title":"Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice","volume":"191","author":"Santini","year":"2000","journal-title":"J Exp Med"}],"updated-by":[{"DOI":"10.3389\/fimmu.2026.1978648","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T00:00:00Z","timestamp":1793750400000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1886898\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T11:31:58Z","timestamp":1793791918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1886898\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":49,"alternative-id":["10.3389\/fimmu.2026.1886898"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1886898","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"article-number":"1886898"}}